Cover Image
Market Research Report
Product code 
1068264

Europe Clinical Trials Market Size, Share & Trends Analysis Report By Study Design (Interventional, Observational, Expanded Access), By Phase (Phase I, Phase II, Phase III, Phase IV), By Region, And Segment Forecasts, 2022 - 2030

Published: | Grand View Research, Inc. | 114 Pages | Delivery time: 2-10 business days

Price

Back to Top
Europe Clinical Trials Market Size, Share & Trends Analysis Report By Study Design (Interventional, Observational, Expanded Access), By Phase (Phase I, Phase II, Phase III, Phase IV), By Region, And Segment Forecasts, 2022 - 2030
Published: March 23, 2022
Grand View Research, Inc.
Content info: 114 Pages
Delivery time: 2-10 business days
  • Description
  • Table of Contents
  • List of Tables

Europe Clinical Trials Market Growth & Trends:

The Europe clinical trials market size is expected to reach USD 20.2 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 5.7% from 2022 to 2030. The rise in technological advancement for clinical trials is one of the key factors driving the market. The growing adoption of new technologies like artificial intelligence, big data analytics, blockchain, clinical trials payments, and patient engagement solutions among others have significantly contributed to the market growth. The COVID-19 pandemic had improved the adoption of virtual clinical trials in the region. Therefore, the growing adoption of new technologies is likely to promote the growth of the market.

The demand for personalized medicines has significantly improved in the region owing to significant research funding for personalized therapies by the European Commission. The aim of various countries in Europe is to collaborate research and health policy to accelerate the adoption of personalized medicine with the formation of the International Consortium for Personalized Medicine, which brings together health research funders and policymaking groups. Such activities are likely to promote market growth. The region suffers from growing disease variation and prevalence. A significant number of people in the region suffer from chronic and rare diseases.

For instance, the European Commission states that approximately 5,000-8,000 distinct rare diseases affect around 6-8% of the European population i.e., between 27 - 36 million. Thus, the high burden of rare diseases is likely to increase the demand for researchers to develop therapeutics for rare diseases. The rising cost associated with research studies has increased the demand for CROs in the region for conducting clinical trials. The partnership agreement between pharmaceutical companies and CROs is likely to promote market growth.

Europe was one the worst affected region by the COVID-19 pandemic, owing to which public organizations in the region made significant funding in research to boost the development of COVID-19 vaccines and diagnostics. For instance, in June 2020 the French president pledged to invest USD 679 million to support the development of COVID-19 vaccines. Owing to the pandemic several research centers were shut down due to the national lockdown implemented by the government authorities, owing to which several clinical trial organizations opted for in silico trials and virtual clinical trials to speed up the research process. Such actions had profited the growth of the market.

Europe Clinical Trials Market Report Highlights:

  • The phase I trial segment is projected to witness a remarkable growth rate of 6.1% over the forecast period. This can be attributed to the significant R&D spending by public and private organizations to support new researches
  • The interventional study design segment held the largest market share of 78.6% in 2021 owing to the greater accuracy offered by these studies, as compared to other clinical study designs
  • European countries such as Germany and the U.K. are spearheading the revenue share, as these have a large patient pool and the presence of advanced medical infrastructure
Product Code: GVR-4-68039-916-5

Table of Content

Chapter 1 Methodology and Scope

  • 1.1 Market Segmentation & Scope
    • 1.1.1 Study Design
    • 1.1.2 Phase
    • 1.1.3 Country Scope
    • 1.1.4 Estimates And Forecast Timeline
  • 1.2 Research Methodology
  • 1.3 Information Procurement
    • 1.3.1 Purchased Database
    • 1.3.2 GVR's Internal Database
    • 1.3.3 Secondary Sources
    • 1.3.4 Primary Research
    • 1.3.5 Details Of Primary Research
  • 1.4 Information or Data Analysis
    • 1.4.1 Data analysis models
  • 1.5 Market Formulation & Validation
  • 1.6 Model Details
    • 1.6.1 Commodity Flow Analysis (Model 1)
    • 1.6.2 Volume Price Analysis (Model 2)
  • 1.7 List of Secondary Sources
  • 1.8 List of Primary Sources
  • 1.9 List of Abbreviations
  • 1.10 Objectives
    • 1.10.1 Objective - 1: Understanding the market dynamics
    • 1.10.2 Objective - 2: Understanding the market estimates and forecasts
    • 1.10.3 Objective - 3: Understanding the attributes such as strategy framework
    • 1.10.4 Objective - 4: Understanding the key service and application scopes to conclude on the market size

Chapter 2 Executive Summary

  • 2.1 Market Outlook
  • 2.2 Segment Outlook

Chapter 3 Europe Clinical Trials Market: Variables, Trends & Scope

  • 3.1 Market Lineage Outlook
    • 3.1.1 PARENT Market OUTLOOK
  • 3.2 Penetration & Growth Prospect Mapping
  • 3.3 Market Dynamics
    • 3.3.1 Market Driver Analysis
      • 3.3.1.1 Growing Adoption Of New Technology In Clinical Research
      • 3.3.1.2 Shift Toward Personalized Medicine
      • 3.3.1.3 Growing Disease Variation And Prevalence
      • 3.3.1.4 Growth In Cro Market
    • 3.3.2 Market Restraint Analysis
      • 3.3.2.1 Regulations In New Drug Development
      • 3.3.2.2 Regulations In New Drug Development
      • 3.3.2.3 Pricing Pressure
  • 3.4. Clinical Category Drivers & Restraints
  • 3.5 Europe clinical trials Market: Analysis Tools
    • 3.5.1 Porter's Five Forces Analysis
    • 3.5.2 Pestel Analysis
    • 3.5.3 Major Deals & Strategic Alliances Analysis
  • 3.6 Analysis of Total Number of Clinical Trial Studies Conducted, by Countries
    • 3.6.1 Analysis of Total Number of Clinical Trial Studies Conducted, by Countries
  • 3.7 Cost Breakdown analysis for CRO's
    • 3.7.1 Percent Of Outsourced Vs In-House Clinical Trial Categories
    • 3.7.2 Cost Breakdown Analysis For Cro's By Phase I, II, & III
    • 3.7.3 Cost Breakdown Analysis For Cro's By Phase I, II, & III FOR Germany
  • 3.8 Covid-19 Impact Analysis

Chapter 4 Europe clinical trials Market: Study Design Segment Analysis

  • 4.1 Europe Clinical Trials Market: Definition & Scope
  • 4.2 Europe Clinical Trials Market: Market Share Analysis, 2021 & 2030
  • 4.3 Interventional Trials
    • 4.3.1 Interventional trials studies market, 2018 - 2030 (USD Million)
  • 4.4 Observational Trials
    • 4.4.1 Observational trials studies market, 2018 - 2030 (USD Million)
  • 4.5 Expanded access Trials
    • 4.5.1 Expanded access studies market, 2018 - 2030 (USD Million)

Chapter 5 Europe clinical trials Market: Phase Segment Analysis

  • 5.1 Europe clinical trials Market: Definition & Scope
  • 5.2 Europe clinical trials Market: Market Share Analysis, 2021 & 2030
  • 5.3 Phase I
    • 5.3.1 Phase I market, 2018 - 2030 (USD Million)
  • 5.4 Phase II
    • 5.4.1 Phase II market, 2018 - 2030 (USD Million)
  • 5.5 Phase III
    • 5.5.1 Phase III market, 2018 - 2030 (USD Million)
  • 5.6 Phase IV
    • 5.6.1 Phase IV market, 2018 - 2030 (USD Million)

Chapter 6 Europe Clinical Trials Market: Country Analysis

  • 6.1 Europe clinical trials Market: Definition & Scope
  • 6.2 Country Market Snapshot
  • 6.3 Country Market Share and Leading Players, 2020
    • 6.3.1 U.K.
    • 6.3.2 Germany
    • 6.3.3 France
    • 6.3.4 Italy
    • 6.3.5 Spain
  • 6.4 Europe clinical trials Market: Market Share Analysis, 2021 & 2030
  • 6.5 Europe
    • 6.5.1 Europe Europe clinical trials market, 2018 - 2030 (USD Million)
    • 6.5.2 U.K.
      • 6.5.2.1 U.K. Europe clinical trials market, 2018 - 2030 (USD Million)
    • 6.5.3 Germany
      • 6.5.3.1 Germany Europe clinical trials market, 2018 - 2030 (USD Million)
    • 6.5.4 France
      • 6.5.4.1 France Europe clinical trials market, 2018 - 2030 (USD Million)
    • 6.5.5 Italy
      • 6.5.5.1 Italy Europe clinical trials market, 2018 - 2030 (USD Million)
    • 6.5.6 Spain
      • 6.5.6.1 Spain Europe clinical trials market, 2018 - 2030 (USD Million)

Chapter 7 Company Profiles

  • 7.1 IQVIA Holdings, Inc.,
      • 7.1.1Company Overview
    • 7.1.2 Financial Performance
    • 7.1.3 Service Benchmarking
    • 7.1.4 Strategic Initiatives
  • 7.2 Parexel International Corporation
    • 7.2.1 Company Overview
    • 7.2.2 Service Benchmarking
    • 7.2.3 Strategic Initiatives
  • 7.3 PPD, Inc.
    • 7.3.1 Company Overview
    • 7.3.2 Financial Performance
    • 7.3.3 Service Benchmarking
    • 7.3.4 Strategic Initiatives
  • 7.4 Syneos Health
    • 7.4.1 Company Overview
    • 7.4.2 Financial Performance
    • 7.4.3 Service Benchmarking
    • 7.4.4 Strategic Initiatives
  • 7.5 Eli Lilly and Company
    • 7.5.1 Company Overview
    • 7.5.2 Financial Performance
    • 7.5.3 Service Benchmarking
    • 7.5.4 Strategic Initiatives
  • 7.6 Novo Nordisk A/S
    • 7.6.1 Company Overview
    • 7.6.2 Financial Performance
    • 7.6.3 Service Benchmarking
    • 7.6.4 Strategic Initiatives
  • 7.7 Pfizer, Inc.
    • 7.7.1 Company Overview
    • 7.7.2 Financial Performance
    • 7.7.3 Service Benchmarking
    • 7.7.4 Strategic Initiatives
  • 7.8 Dr. Notghi Contract Research GmbH
    • 7.8.1 Company Overview
    • 7.8.2 Financial Performance
    • 7.8.3 Service Benchmarking
  • 7.9 Charite Research Organisation GmbH
    • 7.9.1 Company Overview
    • 7.9.2 Financial Performance
    • 7.9.3 Service Benchmarking
    • 7.9.4 Strategic Initiatives
  • 7.10 Janssen Global Services, LLC
    • 7.10.1 Company Overview
    • 7.10.2 Service Benchmarking
    • 7.10.3 Strategic Initiatives
  • 7.11 Janssen Global Services, LLC
    • 7.11.1 Company Overview
    • 7.11.2 Financial Performance
    • 7.11.3 Service Benchmarking
    • 7.11.4 Strategic Initiatives
  • 7.12 KFGN
    • 7.12.1 Company Overview
    • 7.12.2 Financial Performance
    • 7.12.3 Service Benchmarking
  • 7.13 Clariness
    • 7.13.1 Company Overview
    • 7.13.2 Service Benchmarking
  • 7.14 Invisio Clinical Studies Consulting GmbH
    • 7.14.1 Company Overview
    • 7.14.2 Financial Performance
    • 7.14.3 Service Benchmarking

Chapter 8 KOL Commentary

Chapter 9 Recommendations

List of Tables

  • Table 1 List of secondary sources
  • Table 2 List of Abbreviation
  • Table 3 List of Major Deals
  • Table 4 Average cost of clinical trials in major European countries
  • Table 5 Europe Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 6 Europe Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 7 U.K. Clinical trials Market, by Country, 2018 - 2030 (USD Million)
  • Table 8 U.K. Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 9 U.K. Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 10 Germany Clinical trials Market, by Country, 2018 - 2030 (USD Million)
  • Table 11 Germany Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 12 Germany Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 13 France Clinical Trials Market, by Country, 2018 - 2030 (USD Million)
  • Table 14 France Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 15 France Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 16 Italy Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 17 Italy Clinical Trials Market, by Country, 2018 - 2030 (USD Million)
  • Table 18 Italy Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
  • Table 19 Spain Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
  • Table 20 Spain Clinical Trials Market, by Country, 2018 - 2030 (USD Million)
  • Table 21 Spain Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market Research Process
  • Fig. 2 Information of Procurement
  • Fig. 3 Primary research pattern
  • Fig. 4 Market research approaches
  • Fig. 5 QFD modeling for market share assessment
  • Fig. 6 Market formulation & validation
  • Fig. 7 Commodity flow analysis
  • Fig. 8 Volume price analysis
  • Fig. 9 Europe Clinical Trials Market snapshot (2021)
  • Fig. 10 Europe Clinical Trials Market segmentation
  • Fig. 11 Parent market outlook (2021)
  • Fig. 12 Penetration & growth prospect mapping
  • Fig. 13 Market driver relevance analysis (Current & future impact)
  • Fig. 14 Performance on precision medicine availability vs. Biomarker testing by country
  • Fig. 15 Market restraint relevance analysis (Current & future impact)
  • Fig. 16 Clinical Category Drivers & Restraints
  • Fig. 17 Porter's five forces analysis
  • Fig. 18 SWOT analysis, by factor (political & legal, economic and technological)
  • Fig. 19 Germany Cost Per Indication (Million)
  • Fig. 20 U.K. Cost Per Indication (Million)
  • Fig. 21 France Cost Per Indication (Million)
  • Fig. 22 Italy Cost Per Indication (Million)
  • Fig. 23 Spain Cost Per Indication (Million)
  • Fig. 24 Total number of Clinical Trials By Country in 2021
  • Fig. 25 Europe (All Major Countries)
  • Fig. 26 Germany
  • Fig. 27 Europe (Average of all the major countries
  • Fig. 28 Percent of Outsourced vs In-house of Key Clinical Trial Categories (Trend across 2018-2020)
  • Fig. 29 Cost Breakdown by Phase I (Overall Europe)
  • Fig. 30 Cost Breakdown by Phase II (Overall Europe)
  • Fig. 31 Cost Breakdown by Phase III (Overall Europe)
  • Fig. 32 Cost Breakdown by Phase I (Germany)
  • Fig. 33 Cost Breakdown by Phase II (Germany)
  • Fig. 34 Cost Breakdown by Phase III (Germany)
  • Fig. 35 Europe Clinical Trials Market study design outlook: Segment dashboard
  • Fig. 36 Europe Clinical Trials Market: Study design movement analysis
  • Fig. 37 Interventional studies market, 2018 - 2030 (USD Million)
  • Fig. 38 Observational studies market, 2018 - 2030 (USD Million)
  • Fig. 39 Expanded access studies market, 2018 - 2030 (USD Million)
  • Fig. 40 Europe Clinical Trials Market phase outlook: Segment dashboard
  • Fig. 41 Europe Clinical Trials Market: Phase movement analysis
  • Fig. 42 Phase I market, 2018 - 2030 (USD Million)
  • Fig. 43 Phase II market, 2018 - 2030 (USD Million)
  • Fig. 44 Phase III market, 2018 - 2030 (USD Million)
  • Fig. 45 Phase IV market, 2018 - 2030 (USD Million)
  • Fig. 46 Country -wise market: Key takeaways
  • Fig. 47 Country outlook, 2021 & 2030
  • Fig. 48 Europe market, 2018 - 2030 (USD Million)
  • Fig. 49 U.K. market, 2018 - 2030 (USD Million)
  • Fig. 50 Germany market, 2018 - 2030 (USD Million)
  • Fig. 51 France market, 2018 - 2030 (USD Million)
  • Fig. 52 Italy market, 2018 - 2030 (USD Million)
  • Fig. 53 Spain market, 2018 - 2030 (USD Million)